Exact Mass: 471.3712

Exact Mass Matches: 471.3712

Found 128 metabolites which its exact mass value is equals to given mass value 471.3712, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Cervonyl carnitine

3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyloxy]-4-(trimethylazaniumyl)butanoate

C29H45NO4 (471.3348)


Cervonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Cervonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

3-Hydroxyeicosanoylcarnitine

3-[(3-Hydroxyicosanoyl)oxy]-4-(trimethylammonio)butanoic acid

C27H53NO5 (471.3924)


3-Hydroxyeicosanoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyeicosanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyeicosanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Hydroxyeicosanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyicosanoylcarnitine

3-[(2-hydroxyicosanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO5 (471.3924)


2-hydroxyicosanoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyicosanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-hydroxyicosanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 2-hydroxyicosanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-Hydroxyicosanoylcarnitine

3-[(12-hydroxyicosanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO5 (471.3924)


12-hydroxyicosanoylcarnitine is an acylcarnitine. More specifically, it is an 12-hydroxyicosanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-hydroxyicosanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-hydroxyicosanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

15-Hydroxyicosanoylcarnitine

15-Hydroxyicosanoylcarnitine

C27H53NO5 (471.3924)


15-hydroxyicosanoylcarnitine is an acylcarnitine. More specifically, it is an 15-hydroxyicosanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 15-hydroxyicosanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 15-hydroxyicosanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoylcarnitine

3-(docosa-4,7,10,13,16,19-hexaenoyloxy)-4-(trimethylazaniumyl)butanoate

C29H45NO4 (471.3348)


(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Daphnioldhanin F

Daphnioldhanin F

C30H49NO3 (471.3712)


   

Tetrahydrodeoxyoxolucidine A

Tetrahydrodeoxyoxolucidine A

C30H53N3O (471.4188)


   
   

secodaphniphylline

secodaphniphylline

C30H49NO3 (471.3712)


   

Piericidin B4

Piericidin B4

C29H45NO4 (471.3348)


   

methyl (Z)-N-13-docosenoylanthranilate|methyl N-Delta13-docosenoylanthranilate

methyl (Z)-N-13-docosenoylanthranilate|methyl N-Delta13-docosenoylanthranilate

C30H49NO3 (471.3712)


   

Veralosidinine

Veralosidinine

C29H45NO4 (471.3348)


   

Sipeimine, 3-Ac

Sipeimine, 3-Ac

C29H45NO4 (471.3348)


Origin: Plant; SubCategory_DNP: Steroidal alkaloids, Cevanine alkaloids

   

Ile Ile Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]hexanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Ile Ile Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylpentanamido]-3-methylbutanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Ile Lys Ile Val

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-methylpentanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Ile Lys Leu Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-4-methylpentanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Ile Lys Val Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-methylbutanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Ile Lys Val Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-methylbutanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Ile Leu Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-methylpentanamido]hexanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Ile Leu Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-methylpentanamido]-3-methylbutanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Ile Val Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]-3-methylpentanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Ile Val Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]hexanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Ile Val Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]hexanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Ile Val Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-methylbutanamido]-4-methylpentanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Lys Ile Ile Val

(2S)-2-[(2S,3S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-methylpentanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Lys Ile Leu Val

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-4-methylpentanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Lys Ile Val Ile

(2S,3S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-methylbutanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Lys Ile Val Leu

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-methylbutanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Lys Leu Ile Val

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-methylpentanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Lys Leu Leu Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-4-methylpentanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Lys Leu Val Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-methylbutanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Lys Leu Val Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-methylbutanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Lys Val Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-methylpentanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Lys Val Ile Leu

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-methylpentanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Lys Val Leu Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-4-methylpentanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Lys Val Leu Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-4-methylpentanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Leu Ile Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylpentanamido]hexanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Leu Ile Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylpentanamido]-3-methylbutanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Leu Lys Ile Val

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-methylpentanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Leu Lys Leu Val

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-4-methylpentanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Leu Lys Val Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-methylbutanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Leu Lys Val Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-methylbutanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Leu Leu Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-methylpentanamido]hexanamido]-3-methylbutanoic acid

C23H45N5O5 (471.3421)


   

Leu Leu Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-methylpentanamido]-3-methylbutanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Leu Val Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]-3-methylpentanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Leu Val Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]hexanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Leu Val Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]hexanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Leu Val Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-methylbutanamido]-4-methylpentanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Val Ile Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]-3-methylpentanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Val Ile Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]hexanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Val Ile Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]hexanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Val Ile Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylpentanamido]-4-methylpentanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Val Lys Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-methylpentanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Val Lys Ile Leu

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-methylpentanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Val Lys Leu Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-4-methylpentanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Val Lys Leu Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-4-methylpentanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Val Leu Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]-3-methylpentanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Val Leu Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]hexanamido]-3-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Val Leu Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]hexanamido]-4-methylpentanoic acid

C23H45N5O5 (471.3421)


   

Val Leu Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methylpentanamido]-4-methylpentanamido]hexanoic acid

C23H45N5O5 (471.3421)


   

Cervonyl carnitine

Cervonyl carnitine

C29H45NO4 (471.3348)


   

CAR 20:0;O

3-[(3-hydroxyicosanoyl)oxy]-4-(trimethylammonio)butanoate;3-hydroxyarachidoylcarnitine;3-hydroxyicosanoylcarnitine;O-(3-hydroxyarachidoyl)carnitine;O-(3-hydroxyeicosanoyl)carnitine;O-(3-hydroxyicosanoyl)carnitine

C27H53NO5 (471.3924)


   

CAR 22:6

3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyloxy]-4-(trimethylazaniumyl)butanoate

C29H45NO4 (471.3348)


   

n-Hexadecyl-trimethyl-ammonium-3-hydroxy-2-naphthoate

n-Hexadecyl-trimethyl-ammonium-3-hydroxy-2-naphthoate

C30H49NO3 (471.3712)


   

tris(2-hydroxyethyl)ammonium hexadecyl sulphate

tris(2-hydroxyethyl)ammonium hexadecyl sulphate

C22H49NO7S (471.323)


   

bis(2-ethylhexyl) hydrogen phosphate, compound with 2,2,2-nitrilotriethanol (1:1)

bis(2-ethylhexyl) hydrogen phosphate, compound with 2,2,2-nitrilotriethanol (1:1)

C22H50NO7P (471.3325)


   

Hederagenin(1-)

Hederagenin(1-)

C30H47O4- (471.3474)


A monocarboxylic acid anion that is the conjugate base of hederagenin, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

Cochalate

Cochalate

C30H47O4- (471.3474)


A monocarboxylic acid anion resulting from the deprotonation of the carboxy group of cochalic acid. The major species at pH 7.3.

   

2-Hydroxyoleanolate

2-Hydroxyoleanolate

C30H47O4- (471.3474)


   

2-Hydroxyicosanoylcarnitine

2-Hydroxyicosanoylcarnitine

C27H53NO5 (471.3924)


   

12-Hydroxyicosanoylcarnitine

12-Hydroxyicosanoylcarnitine

C27H53NO5 (471.3924)


   

15-Hydroxyicosanoylcarnitine

15-Hydroxyicosanoylcarnitine

C27H53NO5 (471.3924)


   

[3-carboxy-2-[(Z)-10-nitrooctadec-9-enoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(Z)-10-nitrooctadec-9-enoyl]oxypropyl]-trimethylazanium

C25H47N2O6+ (471.3434)


   

[3-carboxy-2-[(Z)-9-nitrooctadec-9-enoyl]oxypropyl]-trimethylazanium

[3-carboxy-2-[(Z)-9-nitrooctadec-9-enoyl]oxypropyl]-trimethylazanium

C25H47N2O6+ (471.3434)


   

Car(DC19:0)

Car(DC19:0)

C26H49NO6 (471.356)


   

(17Z,20Z,23Z,26Z)-dotriacontatetraenoate

(17Z,20Z,23Z,26Z)-dotriacontatetraenoate

C32H55O2- (471.4202)


A polyunsaturated fatty acid anion that is the conjugate base of (17Z,20Z,23Z,26Z)-dotriacontatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

21-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]henicosanoate

21-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]henicosanoate

C27H51O6- (471.3685)


   

20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxoicosanoate

20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxoicosanoate

C26H47O7- (471.3322)


   

(19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxoicosanoate

(19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxoicosanoate

C26H47O7- (471.3322)


   

(20R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyhenicosanoate

(20R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyhenicosanoate

C27H51O6- (471.3685)


   
   

(7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docosa-7,10,13,16,19-pentaenamide

(7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docosa-7,10,13,16,19-pentaenamide

C30H49NO3 (471.3712)


   

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

C30H49NO3 (471.3712)


   

(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide

(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide

C30H49NO3 (471.3712)


   

(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide

C30H49NO3 (471.3712)


   

(7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadeca-7,10,13-trienamide

(7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadeca-7,10,13-trienamide

C30H49NO3 (471.3712)


   

(6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadeca-6,9,12,15-tetraenamide

C30H49NO3 (471.3712)


   

(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide

C30H49NO3 (471.3712)


   

Cer 9:0;3O/18:1;(2OH)

Cer 9:0;3O/18:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 8:0;3O/19:1;(2OH)

Cer 8:0;3O/19:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 11:0;3O/16:1;(2OH)

Cer 11:0;3O/16:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 12:1;3O/15:0;(2OH)

Cer 12:1;3O/15:0;(2OH)

C27H53NO5 (471.3924)


   

Cer 13:0;3O/14:1;(2OH)

Cer 13:0;3O/14:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 13:1;3O/14:0;(2OH)

Cer 13:1;3O/14:0;(2OH)

C27H53NO5 (471.3924)


   

Cer 12:0;3O/15:1;(2OH)

Cer 12:0;3O/15:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 15:1;3O/12:0;(2OH)

Cer 15:1;3O/12:0;(2OH)

C27H53NO5 (471.3924)


   

Cer 15:0;3O/12:1;(2OH)

Cer 15:0;3O/12:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 14:1;3O/13:0;(2OH)

Cer 14:1;3O/13:0;(2OH)

C27H53NO5 (471.3924)


   

Cer 14:0;3O/13:1;(2OH)

Cer 14:0;3O/13:1;(2OH)

C27H53NO5 (471.3924)


   

lysoDGTS 16:1

lysoDGTS 16:1

C26H49NO6 (471.356)


   

3-hydroxyeicosanoylcarnitine

3-hydroxyeicosanoylcarnitine

C27H53NO5 (471.3924)


An O-acylcarnitine having 3-hydroxyeicosanoyl as the acyl substituent.

   

oscr#38(1-)

oscr#38(1-)

C27H51O6 (471.3685)


A hydroxy fatty acid ascaroside anion resulting from the deprotonation of the carboxy group of oscr#38. The conjugate base of oscr#38 and the major species at pH 7.3.

   

dotriacontatetraenoate

dotriacontatetraenoate

C32H55O2 (471.4202)


A polyunsaturated fatty acid anion that is the conjugate base of dotriacontatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#38(1-)

ascr#38(1-)

C27H51O6 (471.3685)


Conjugate base of ascr#38

   
   

NA-Dopamine 22:2(13Z,16Z)

NA-Dopamine 22:2(13Z,16Z)

C30H49NO3 (471.3712)


   
   

NA-Tyr 20:2(11Z,14Z)

NA-Tyr 20:2(11Z,14Z)

C29H45NO4 (471.3348)


   
   
   
   

ST 27:3;O2;Gly

ST 27:3;O2;Gly

C29H45NO4 (471.3348)


   

1-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl}propan-1-one

1-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl}propan-1-one

C30H49NO3 (471.3712)


   

(1s,2s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

(1s,2s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

C30H49NO3 (471.3712)


   

5-[(1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl)methyl]-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

5-[(1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl)methyl]-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

C30H53N3O (471.4188)


   

(1s,2s,5s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

(1s,2s,5s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

C30H49NO3 (471.3712)


   

n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid

n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid

C30H49NO3 (471.3712)


   

2-methyl-6-(13-oxotetradecyl)piperidin-3-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

2-methyl-6-(13-oxotetradecyl)piperidin-3-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C29H45NO4 (471.3348)


   

2,3-dimethoxy-6-(10-methoxy-3,5,7,9,11,13-hexamethyltetradeca-2,5,7,11-tetraen-1-yl)-5-methylpyridin-4-ol

2,3-dimethoxy-6-(10-methoxy-3,5,7,9,11,13-hexamethyltetradeca-2,5,7,11-tetraen-1-yl)-5-methylpyridin-4-ol

C29H45NO4 (471.3348)


   

(13z)-n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid

(13z)-n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid

C30H49NO3 (471.3712)


   

2-methyl-6-(13-oxotetradecyl)piperidin-3-yl 3-(4-hydroxyphenyl)prop-2-enoate

2-methyl-6-(13-oxotetradecyl)piperidin-3-yl 3-(4-hydroxyphenyl)prop-2-enoate

C29H45NO4 (471.3348)


   

1-[(1r,4r,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1s,2r,3r,7s,10s,13s,14r)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl]propan-1-one

1-[(1r,4r,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1s,2r,3r,7s,10s,13s,14r)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl]propan-1-one

C30H49NO3 (471.3712)


   

2,3-dimethoxy-6-[(2e,5e,7e,9s,10s,11e)-10-methoxy-3,5,7,9,11,13-hexamethyltetradeca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-ol

2,3-dimethoxy-6-[(2e,5e,7e,9s,10s,11e)-10-methoxy-3,5,7,9,11,13-hexamethyltetradeca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-ol

C29H45NO4 (471.3348)


   

8-(2-{14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl}ethyl)-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

8-(2-{14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl}ethyl)-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

C30H49NO3 (471.3712)


   

(1r,2s,5r,7s,9s,11r,13s,17r)-5-{[(4ar,5r,7s,8as)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

(1r,2s,5r,7s,9s,11r,13s,17r)-5-{[(4ar,5r,7s,8as)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

C30H53N3O (471.4188)


   

(1r,2s,5s,7s,9s,11r,13s,17r)-5-{[(4as,5r,7s,8ar)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

(1r,2s,5s,7s,9s,11r,13s,17r)-5-{[(4as,5r,7s,8ar)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

C30H53N3O (471.4188)